Balyasny Asset Management
ESPR

Balyasny Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Balyasny Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.7M Buy
+4,654,778
New +$13M 0.02% 878
2025
Q4 		– Sell
-115,624
Closed -$306K – 3216
2025
Q3 		$306K Buy
+115,624
New +$224K ﹤0.01% 2570
2024
Q2 		– Sell
-159,038
Closed -$426K – 2709
2024
Q1 		$426K Buy
159,038
+121,850
+328% +$296K ﹤0.01% 2113
2023
Q4 		$111K Buy
+37,188
New +$48.2K ﹤0.01% 2374
2023
Q3 		– Sell
-16,039
Closed -$22.3K – 2381
2023
Q2 		$22.3K Sell
16,039
-4,755,321
-100% -$6.64M ﹤0.01% 2155
2023
Q1 		$7.59M Buy
4,771,360
+1,342,223
+39% +$6.93M 0.02% 893
2022
Q4 		$21.4M Buy
3,429,137
+2,633,466
+331% +$18.8M 0.06% 466
2022
Q3 		$5.33M Buy
795,671
+783,700
+6,547% +$5.38M 0.02% 957
2022
Q2 		$76K Buy
+11,971
New +$67.9K ﹤0.01% 2312
2020
Q3 		– Sell
-62,282
Closed -$2.47M – 1380
2020
Q2 		$3.2M Sell
62,282
-199,456
-76% -$8.35M 0.03% 621
2020
Q1 		$8.25M Buy
261,738
+11,361
+5% +$600K 0.1% 286
2019
Q4 		$14.9M Buy
250,377
+115,147
+85% +$5.18M 0.09% 323
2019
Q3 		$4.96M Sell
135,230
-26,218
-16% -$1.04M 0.03% 550
2019
Q2 		$7.51M Buy
+161,448
New +$7.58M 0.05% 487
2018
Q4 		– Sell
-9,894
Closed -$477K – 1487
2018
Q3 		$439K Sell
9,894
-31,330
-76% -$1.44M ﹤0.01% 1416
2018
Q2 		$1.62M Sell
41,224
-109,217
-73% -$5.52M 0.01% 1005
2018
Q1 		$10.9M Sell
150,441
-252,723
-63% -$18.6M 0.05% 500
2017
Q4 		$26.5M Buy
403,164
+10,014
+3% +$539K 0.08% 323
2017
Q3 		$19.7M Buy
393,150
+192,667
+96% +$9.29M 0.08% 330
2017
Q2 		$9.28M Buy
200,483
+150,983
+305% +$5.55M 0.04% 562
2017
Q1 		$1.75M Buy
+49,500
New +$1.13M 0.01% 945

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Balyasny Asset Management's ESPR Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 4,654,778 shares worth $14.7M. The stake represents 0.02% of the portfolio and ranks #878 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in ESPR as recently as Q3 2025.

Balyasny Asset Management first reported a position in ESPR in Q1 2017 and has held it in 21 quarters since. The position peaked at $26.5M in Q4 2017. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Balyasny Asset Management held 4,654,778 shares of Esperion Therapeutics worth $14.7M as of Q2 2026.
  • Esperion Therapeutics was a new Balyasny Asset Management position in Q2 2026.
  • Esperion Therapeutics made up 0.02% of Balyasny Asset Management's portfolio in Q2 2026, its #878 holding.
  • Balyasny Asset Management first reported a position in Esperion Therapeutics in Q1 2017 and has held it in 21 quarters since.
  • Balyasny Asset Management's Esperion Therapeutics position peaked at $26.5M in Q4 2017.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.